US Congress Adds Psychedelics Studies to Defense Bill

The psychedelic renaissance continues to gain legitimacy, supported by the most unlikely of allies — the United States military. 

This week a bipartisan group of congressional lawmakers from both the House and the Senate have agreed to add funding for studies of psychedelic therapies into a major defense bill.

The 2024 National Defense Authorization Act (NDAA) passed on Wednesday and included the provision for psychedelics research introduced by Republican lawmakers like Rep. Morgan Luttrell of Texas.

The bill’s psychedelic sections require the Department of Defense (DOD) to facilitate access for military veterans to clinical trials for the treatment of PTSD or traumatic brain injury. The provisions allow for participating in studies using psilocybin, MDMA, ibogaine and 5-MeO-DMT (and “qualified plant-based alternative therapies”).

This isn’t a suggestion but a requirement, one that forces the Department of Defense to facilitate access for military service members, in addition to providing $10 million in funding, and partnerships with agencies and academic institutions doing psychedelic research.

Another major step forward for institutional acceptance of psychedelic therapies. 

The times they are indeed a changing

For more on military support of psychedelics, check out Republican Lawmakers Introduce New Bill for Psychedelic Therapy

The post US Congress Adds Psychedelics Studies to Defense Bill appeared first on Microdose.

ibogaine
psilocybin
mdma
dmt
psychedelic
therapy
ptsd